Heart disease is a major health concern in the United States and remains the leading cause of death.
Traditional treatments to control risk factors, such as blood pressure and cholesterol medications, have helped but haven’t fully addressed the problem.
However, a recent study conducted by researchers at the University of Michigan has discovered a protein that could provide new insights into treating both heart disease and kidney disease.
The protein in question is called soluble urokinase plasminogen activator receptor, or suPAR for short. It is produced by the bone marrow and acts as a regulator for the immune system.
What is suPAR?
SuPAR, also known as an “immunostat,” helps control the activity of the immune system.
Previous studies have identified suPAR as a marker for cardiovascular disease, but this new research reveals that high levels of suPAR can actually cause atherosclerosis.
Understanding Atherosclerosis
Atherosclerosis is a condition that affects over a billion people worldwide and involves the hardening of arteries. It is a significant factor in heart disease.
The Study Findings
The research team analyzed data from over 5,000 individuals without known heart disease and found a strong correlation between higher suPAR levels and the development of atherosclerosis, regardless of other risk factors.
They also conducted a genetic study involving 24,000 people to investigate how genetic variations affect suPAR levels.
They identified a specific genetic variant in the PLAUR gene, responsible for suPAR production. Individuals with this variant tended to have higher suPAR levels.
Importantly, the researchers discovered that this genetic variant was linked to atherosclerosis in a larger analysis involving 500,000 participants. The findings were further validated in two additional large datasets.
Mouse Models Confirm the Findings
To further explore the role of suPAR, the researchers conducted experiments using mouse models. Mice with high suPAR levels showed a significant increase in atherosclerotic plaques in their arteries compared to mice with normal suPAR levels.
Implications for Treatment
These groundbreaking findings have paved the way for potential new treatments.
Traditional therapies for atherosclerosis have shown no impact on suPAR levels, but the researchers are now focused on developing strategies to safely reduce suPAR levels. This approach could offer a promising way to prevent and treat heart disease.
Link to Kidney Disease
The study also revealed that suPAR is a key factor in causing kidney disease, which affects a substantial portion of the American population.
People often experience both heart and kidney disease simultaneously, and there is a significant overlap between the two conditions.
Moving Forward
The researchers are determined to advance their findings and explore possible treatments that target suPAR to combat heart and kidney disease.
This represents a major breakthrough in understanding these complex diseases and offers hope for improved treatments in the future.
Heart disease and kidney disease are serious health issues affecting many people worldwide.
The discovery of suPAR’s role in causing atherosclerosis and kidney disease opens up new possibilities for developing innovative treatments.
Further research and clinical trials are needed to fully understand the potential of reducing suPAR levels as a therapeutic strategy.
These findings mark an important step toward addressing the challenges posed by these widespread health conditions and improving patient outcomes.
If you care about kidney health, please read studies that the Mediterranean diet could help protect kidney health, and the DASH diet for high blood pressure can protect kidney health.
For more information about kidney health, please see recent studies about a drug that prevents kidney failure in diabetes, and results showing cruciferous vegetables may reduce kidney damage in diabetes.
Copyright © 2023 Knowridge Science Report. All rights reserved.
